Latest Content

Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, discusses end-of-life care from a multidisciplinary perspective.

Oncology nurses and APPs are key players in patient education on precision medicine.

Subcutaneous mosunetuzumab wins FDA accelerated approval in patients with R/R follicular lymphoma following 2 or more lines of systemic therapy.

Breast cancer survivors improved cognitive outcomes with both real and sham acupuncture, but real acupuncture showed greater gains.

As CAR T-cell therapy expands to solid tumors, oncology nurses play a key role in monitoring, educating, and supporting patients.

Giredestrant displayed a safety profile consistent with prior findings and had a lower rate of discontinuation compared with standard endocrine therapy.

Frontline maintenance tucatinib plus trastuzumab and pertuzumab increased progression-free survival in patient with HER2-positive metastatic breast cancer.

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj across all amivantamab indications.

The FDA has greenlit treatment with rucaparib for previously treated patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Hormone replacement therapy was associated with a lower risk of developing BRCA1– or BRCA2–mutated breast cancer among those already at higher risk.

The treatment combination of T-DXd and pertuzumab was granted FDA approval in the first-line for unresectable or metastatic HER2-positive breast cancer.

The FDA has approved niraparib and abiraterone acetate with prednisone for the treatment of patients with BRCA2-mutated metastatic hormone-sensitive prostate cancer.

Subcutaneous daratumumab plus teclistamab improved survival outcomes in patients with R/R multiple myeloma vs standard daratumumab-based regimens.